| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fatigue | 31 | 2021 | 1239 | 3.720 |
Why?
|
| Minocycline | 3 | 2021 | 182 | 1.940 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2023 | 799 | 1.920 |
Why?
|
| Pain | 21 | 2021 | 1658 | 1.350 |
Why?
|
| Severity of Illness Index | 37 | 2021 | 4320 | 1.290 |
Why?
|
| Genital Neoplasms, Female | 3 | 2021 | 735 | 1.210 |
Why?
|
| Health Status Indicators | 8 | 2015 | 224 | 1.110 |
Why?
|
| Health Surveys | 9 | 2013 | 402 | 1.090 |
Why?
|
| Neoplasms | 40 | 2014 | 15193 | 1.020 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2023 | 356 | 0.990 |
Why?
|
| Symptom Assessment | 3 | 2021 | 267 | 0.900 |
Why?
|
| Foraminifera | 1 | 2022 | 1 | 0.900 |
Why?
|
| Seawater | 1 | 2022 | 12 | 0.900 |
Why?
|
| Cost of Illness | 9 | 2016 | 498 | 0.860 |
Why?
|
| Surveys and Questionnaires | 27 | 2015 | 5687 | 0.850 |
Why?
|
| Pain Measurement | 8 | 2014 | 953 | 0.840 |
Why?
|
| Multiple Myeloma | 7 | 2021 | 2138 | 0.800 |
Why?
|
| Quality of Life | 19 | 2021 | 4532 | 0.750 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2019 | 5319 | 0.750 |
Why?
|
| Chemoradiotherapy | 4 | 2019 | 1946 | 0.750 |
Why?
|
| Language | 5 | 2010 | 309 | 0.740 |
Why?
|
| Perioperative Care | 2 | 2021 | 451 | 0.720 |
Why?
|
| Patient Discharge | 2 | 2023 | 661 | 0.700 |
Why?
|
| Psychometrics | 9 | 2019 | 937 | 0.670 |
Why?
|
| Sickness Impact Profile | 9 | 2013 | 139 | 0.610 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 294 | 0.600 |
Why?
|
| Interleukin-6 | 3 | 2012 | 1038 | 0.600 |
Why?
|
| Peripheral Nervous System Diseases | 6 | 2019 | 393 | 0.580 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2992 | 0.580 |
Why?
|
| Lung Neoplasms | 12 | 2019 | 11538 | 0.580 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2012 | 600 | 0.570 |
Why?
|
| Middle Aged | 72 | 2021 | 86204 | 0.560 |
Why?
|
| Reproducibility of Results | 20 | 2021 | 6009 | 0.550 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 521 | 0.540 |
Why?
|
| Pain Management | 5 | 2012 | 668 | 0.530 |
Why?
|
| Longitudinal Studies | 8 | 2021 | 1945 | 0.520 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2012 | 77 | 0.500 |
Why?
|
| Aged | 61 | 2019 | 70117 | 0.500 |
Why?
|
| Inflammation Mediators | 2 | 2014 | 423 | 0.490 |
Why?
|
| Female | 78 | 2023 | 141928 | 0.480 |
Why?
|
| Radiosurgery | 6 | 2014 | 1330 | 0.470 |
Why?
|
| China | 10 | 2010 | 606 | 0.440 |
Why?
|
| Male | 72 | 2019 | 123000 | 0.420 |
Why?
|
| Radiotherapy | 4 | 2014 | 1824 | 0.420 |
Why?
|
| Humans | 91 | 2023 | 261506 | 0.420 |
Why?
|
| Cytokines | 6 | 2014 | 2809 | 0.410 |
Why?
|
| Adult | 51 | 2019 | 77950 | 0.410 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1763 | 0.400 |
Why?
|
| Self Report | 5 | 2016 | 756 | 0.390 |
Why?
|
| Colorectal Neoplasms | 5 | 2019 | 3578 | 0.380 |
Why?
|
| Aged, 80 and over | 30 | 2019 | 29902 | 0.380 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 142 | 0.380 |
Why?
|
| Spinal Cord Compression | 1 | 2012 | 151 | 0.380 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 902 | 0.370 |
Why?
|
| Combined Modality Therapy | 8 | 2014 | 8865 | 0.360 |
Why?
|
| Cultural Characteristics | 1 | 2010 | 70 | 0.360 |
Why?
|
| Double-Blind Method | 3 | 2021 | 2588 | 0.360 |
Why?
|
| Attitude of Health Personnel | 3 | 2006 | 918 | 0.360 |
Why?
|
| Proof of Concept Study | 2 | 2019 | 53 | 0.350 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1870 | 0.350 |
Why?
|
| Perioperative Period | 2 | 2021 | 155 | 0.340 |
Why?
|
| Prospective Studies | 11 | 2023 | 12873 | 0.340 |
Why?
|
| Spinal Neoplasms | 5 | 2014 | 631 | 0.340 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 14289 | 0.330 |
Why?
|
| Patient Outcome Assessment | 3 | 2015 | 245 | 0.320 |
Why?
|
| Sleep Wake Disorders | 7 | 2014 | 348 | 0.320 |
Why?
|
| Korea | 7 | 2010 | 63 | 0.310 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2006 | 1303 | 0.300 |
Why?
|
| Proton Therapy | 1 | 2016 | 1577 | 0.260 |
Why?
|
| Cognition Disorders | 3 | 2019 | 786 | 0.260 |
Why?
|
| Cross-Sectional Studies | 9 | 2021 | 4314 | 0.250 |
Why?
|
| Urban Health Services | 1 | 2004 | 37 | 0.240 |
Why?
|
| Russia | 3 | 2010 | 54 | 0.240 |
Why?
|
| Dyspnea | 3 | 2019 | 416 | 0.230 |
Why?
|
| Inflammation | 3 | 2010 | 2522 | 0.230 |
Why?
|
| Emergency Medical Services | 1 | 2008 | 429 | 0.230 |
Why?
|
| Patient Care Management | 1 | 2004 | 94 | 0.230 |
Why?
|
| Pacific Ocean | 1 | 2022 | 7 | 0.230 |
Why?
|
| Oceans and Seas | 1 | 2022 | 10 | 0.220 |
Why?
|
| Terminal Care | 2 | 2007 | 447 | 0.220 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2007 | 1039 | 0.220 |
Why?
|
| Professional Competence | 1 | 2004 | 136 | 0.220 |
Why?
|
| Risk Assessment | 5 | 2013 | 6869 | 0.210 |
Why?
|
| Socioeconomic Factors | 4 | 2012 | 1225 | 0.210 |
Why?
|
| Adolescent | 18 | 2015 | 31252 | 0.200 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 5112 | 0.200 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 10001 | 0.190 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2013 | 901 | 0.180 |
Why?
|
| Biomarkers | 3 | 2021 | 5047 | 0.180 |
Why?
|
| Data Collection | 4 | 2007 | 620 | 0.180 |
Why?
|
| Survivors | 3 | 2014 | 1031 | 0.170 |
Why?
|
| Prevalence | 6 | 2014 | 3260 | 0.170 |
Why?
|
| Affect | 3 | 2013 | 288 | 0.170 |
Why?
|
| Postoperative Period | 1 | 2021 | 665 | 0.170 |
Why?
|
| Taiwan | 3 | 2008 | 93 | 0.160 |
Why?
|
| Fluorouracil | 2 | 2009 | 1944 | 0.160 |
Why?
|
| Oxygen | 1 | 2022 | 754 | 0.160 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 406 | 0.160 |
Why?
|
| Rectal Neoplasms | 2 | 2009 | 1202 | 0.160 |
Why?
|
| Patients | 1 | 2020 | 245 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2014 | 6550 | 0.160 |
Why?
|
| Pain, Intractable | 1 | 1999 | 171 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2019 | 700 | 0.160 |
Why?
|
| Postoperative Complications | 3 | 2023 | 5542 | 0.150 |
Why?
|
| Palliative Care | 4 | 2004 | 2037 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2009 | 1299 | 0.140 |
Why?
|
| Neuroimmunomodulation | 2 | 2008 | 66 | 0.140 |
Why?
|
| Length of Stay | 1 | 2023 | 1900 | 0.140 |
Why?
|
| Stress, Psychological | 3 | 2014 | 1000 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 4 | 2014 | 3976 | 0.130 |
Why?
|
| Comorbidity | 5 | 2013 | 2352 | 0.130 |
Why?
|
| Japan | 4 | 2010 | 227 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2014 | 2231 | 0.130 |
Why?
|
| Logistic Models | 4 | 2014 | 3441 | 0.120 |
Why?
|
| Pediatrics | 1 | 2003 | 1141 | 0.120 |
Why?
|
| Transplantation, Autologous | 3 | 2014 | 1914 | 0.120 |
Why?
|
| Fingers | 1 | 2014 | 120 | 0.120 |
Why?
|
| Health Care Surveys | 2 | 2006 | 430 | 0.120 |
Why?
|
| Anorexia | 2 | 2014 | 143 | 0.110 |
Why?
|
| Hypesthesia | 1 | 2013 | 22 | 0.110 |
Why?
|
| Leukemia | 1 | 2002 | 1635 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 311 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2019 | 1987 | 0.110 |
Why?
|
| Karnofsky Performance Status | 2 | 2010 | 175 | 0.110 |
Why?
|
| Leukocyte Count | 1 | 2014 | 684 | 0.110 |
Why?
|
| Central Nervous System | 1 | 2014 | 436 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2014 | 332 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 702 | 0.100 |
Why?
|
| Pain, Postoperative | 2 | 2014 | 610 | 0.100 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2010 | 726 | 0.100 |
Why?
|
| Time Factors | 7 | 2014 | 12926 | 0.100 |
Why?
|
| Radiation Dosage | 1 | 2016 | 1014 | 0.100 |
Why?
|
| Hospitals, Public | 1 | 2011 | 64 | 0.100 |
Why?
|
| Liver | 1 | 2021 | 2961 | 0.100 |
Why?
|
| Feeding and Eating Disorders | 1 | 2012 | 97 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2014 | 2307 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2014 | 431 | 0.100 |
Why?
|
| Morocco | 1 | 2010 | 5 | 0.100 |
Why?
|
| Philippines | 2 | 2010 | 39 | 0.100 |
Why?
|
| Medically Underserved Area | 1 | 2011 | 101 | 0.090 |
Why?
|
| Sensitivity and Specificity | 6 | 2013 | 4971 | 0.090 |
Why?
|
| Mucositis | 2 | 2008 | 148 | 0.090 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 669 | 0.090 |
Why?
|
| Neoplasm Staging | 5 | 2014 | 13658 | 0.090 |
Why?
|
| Reminder Systems | 1 | 2011 | 83 | 0.090 |
Why?
|
| Translating | 1 | 2010 | 45 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2014 | 2326 | 0.090 |
Why?
|
| Factor Analysis, Statistical | 5 | 2011 | 356 | 0.090 |
Why?
|
| Risk Factors | 8 | 2013 | 17523 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 482 | 0.090 |
Why?
|
| Thoracotomy | 1 | 2011 | 220 | 0.090 |
Why?
|
| Mental Recall | 1 | 2010 | 171 | 0.090 |
Why?
|
| Translations | 2 | 2010 | 39 | 0.080 |
Why?
|
| Chronobiology Disorders | 1 | 2008 | 10 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2013 | 785 | 0.080 |
Why?
|
| Texas | 5 | 2014 | 6311 | 0.080 |
Why?
|
| Kidney Neoplasms | 2 | 2014 | 3022 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2012 | 1546 | 0.080 |
Why?
|
| Young Adult | 7 | 2015 | 21445 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1516 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 672 | 0.080 |
Why?
|
| Residence Characteristics | 3 | 2010 | 348 | 0.080 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 252 | 0.080 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2009 | 292 | 0.080 |
Why?
|
| Personality Inventory | 1 | 2008 | 178 | 0.080 |
Why?
|
| Interleukin-10 | 1 | 2010 | 478 | 0.070 |
Why?
|
| Radiation Pneumonitis | 1 | 2009 | 301 | 0.070 |
Why?
|
| Health Status | 2 | 2011 | 590 | 0.070 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2007 | 216 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 598 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2006 | 497 | 0.060 |
Why?
|
| Telemedicine | 1 | 2011 | 471 | 0.060 |
Why?
|
| Depressive Disorder | 2 | 2013 | 557 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 1538 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 14889 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2012 | 2203 | 0.060 |
Why?
|
| Sensory Thresholds | 2 | 2014 | 68 | 0.060 |
Why?
|
| Activities of Daily Living | 2 | 2009 | 552 | 0.060 |
Why?
|
| Skin Temperature | 2 | 2014 | 32 | 0.060 |
Why?
|
| Depression | 1 | 2013 | 1715 | 0.060 |
Why?
|
| Radiation Injuries | 2 | 2008 | 1411 | 0.060 |
Why?
|
| Radiotherapy Dosage | 3 | 2012 | 3842 | 0.060 |
Why?
|
| Exercise Tolerance | 1 | 2003 | 107 | 0.060 |
Why?
|
| Case-Control Studies | 5 | 2014 | 6100 | 0.060 |
Why?
|
| Acute Disease | 2 | 2013 | 2422 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2006 | 915 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 2594 | 0.050 |
Why?
|
| Incidence | 2 | 2014 | 5673 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 2843 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 3719 | 0.050 |
Why?
|
| Sleep Stages | 2 | 2014 | 78 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 4938 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2002 | 257 | 0.050 |
Why?
|
| Models, Animal | 1 | 2003 | 664 | 0.050 |
Why?
|
| Sleep | 1 | 2003 | 413 | 0.050 |
Why?
|
| Cancer Care Facilities | 3 | 2014 | 884 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2003 | 709 | 0.040 |
Why?
|
| Models, Biological | 1 | 2008 | 3254 | 0.040 |
Why?
|
| Physicians | 2 | 2013 | 882 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 4638 | 0.040 |
Why?
|
| United States | 3 | 2011 | 15433 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3890 | 0.040 |
Why?
|
| Analgesics, Opioid | 2 | 2014 | 1371 | 0.040 |
Why?
|
| Prognosis | 3 | 2013 | 21713 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 3168 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 792 | 0.040 |
Why?
|
| Bone Neoplasms | 2 | 2001 | 2576 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 4549 | 0.040 |
Why?
|
| Psychological Tests | 2 | 2008 | 131 | 0.040 |
Why?
|
| Deglutition Disorders | 2 | 2013 | 447 | 0.040 |
Why?
|
| Attitude to Health | 1 | 1999 | 465 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 418 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 4892 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2004 | 1423 | 0.030 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2014 | 16 | 0.030 |
Why?
|
| Vinca Alkaloids | 1 | 2014 | 9 | 0.030 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2014 | 12 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2003 | 1429 | 0.030 |
Why?
|
| Cyclohexanols | 1 | 2014 | 15 | 0.030 |
Why?
|
| Salpingectomy | 1 | 2015 | 43 | 0.030 |
Why?
|
| Carbamazepine | 1 | 2014 | 49 | 0.030 |
Why?
|
| Amitriptyline | 1 | 2014 | 38 | 0.030 |
Why?
|
| Epothilones | 1 | 2014 | 54 | 0.030 |
Why?
|
| Sensorimotor Cortex | 1 | 2014 | 22 | 0.030 |
Why?
|
| Cold Temperature | 1 | 2014 | 121 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2014 | 245 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2014 | 209 | 0.030 |
Why?
|
| Thiophenes | 1 | 2014 | 148 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2015 | 330 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2014 | 281 | 0.030 |
Why?
|
| Netherlands | 1 | 2013 | 83 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 15862 | 0.030 |
Why?
|
| Stomatitis | 1 | 2014 | 183 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 543 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2014 | 362 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 422 | 0.030 |
Why?
|
| Executive Function | 1 | 2013 | 160 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 4988 | 0.030 |
Why?
|
| Mass Screening | 2 | 2013 | 1509 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2012 | 32848 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 663 | 0.030 |
Why?
|
| Sensation | 1 | 2012 | 71 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 1085 | 0.030 |
Why?
|
| Pyrazines | 1 | 2014 | 495 | 0.030 |
Why?
|
| Pharyngitis | 1 | 2011 | 41 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6207 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2015 | 611 | 0.020 |
Why?
|
| Thalidomide | 1 | 2014 | 569 | 0.020 |
Why?
|
| Neuralgia | 1 | 2014 | 251 | 0.020 |
Why?
|
| Electronic Mail | 1 | 2011 | 53 | 0.020 |
Why?
|
| Taxoids | 1 | 2014 | 967 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2014 | 629 | 0.020 |
Why?
|
| Telephone | 1 | 2011 | 163 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 1972 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 4298 | 0.020 |
Why?
|
| Memory | 1 | 2013 | 429 | 0.020 |
Why?
|
| Learning | 1 | 2013 | 403 | 0.020 |
Why?
|
| Constipation | 1 | 2011 | 177 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2014 | 1450 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2013 | 627 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2013 | 554 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2009 | 239 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2008 | 96 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 750 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2803 | 0.020 |
Why?
|
| Taste Disorders | 1 | 2007 | 17 | 0.020 |
Why?
|
| Mastication | 1 | 2007 | 19 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2007 | 15 | 0.020 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2007 | 30 | 0.020 |
Why?
|
| Capecitabine | 1 | 2009 | 388 | 0.020 |
Why?
|
| Mitochondria | 1 | 2014 | 1282 | 0.020 |
Why?
|
| Epidural Space | 1 | 2007 | 42 | 0.020 |
Why?
|
| Voice Disorders | 1 | 2007 | 39 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2011 | 739 | 0.020 |
Why?
|
| Child | 2 | 2008 | 29154 | 0.020 |
Why?
|
| Chest Pain | 1 | 2007 | 155 | 0.020 |
Why?
|
| Xerostomia | 1 | 2007 | 190 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 2316 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 1163 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 415 | 0.020 |
Why?
|
| Anxiety | 1 | 2013 | 1179 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 761 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 2170 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 1391 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 1544 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 2003 | 136 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2009 | 1353 | 0.010 |
Why?
|
| Europe | 1 | 2005 | 649 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 1819 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 3203 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 7702 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1999 | 4557 | 0.010 |
Why?
|
| Remission Induction | 1 | 2009 | 3569 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 589 | 0.010 |
Why?
|
| Exercise Test | 1 | 2003 | 312 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2012 | 10035 | 0.010 |
Why?
|
| Hospitals, General | 1 | 2001 | 27 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 4109 | 0.010 |
Why?
|
| Analgesics | 1 | 2004 | 390 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 37905 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 2055 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2001 | 118 | 0.010 |
Why?
|
| Recurrence | 1 | 2008 | 4758 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 5377 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 2139 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 2238 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 6682 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 4975 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2007 | 9180 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 5539 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1999 | 15694 | 0.010 |
Why?
|
| Algorithms | 1 | 2006 | 3890 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 9244 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2001 | 1209 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 7551 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 59536 | 0.000 |
Why?
|